Discover more insights into Virion Inactivated 病毒粒子灭活

Keywords frequently search together with Virion Inactivated 病毒粒子灭活

Narrow sentence examples with built-in keyword filters

Virion Inactivated sentence examples within receptor 7 8



Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial


Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Virion Inactivated sentence examples within Whole Virion Inactivated



COVID‐19 vaccine‐induced urticarial vasculitis


Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation

Virion Inactivated sentence examples within virion inactivated sar



Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial


Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial


Learn more from Virion Inactivated 病毒粒子灭活


Virion Inactivated sentence examples within virion inactivated influenza



Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season


Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India

Virion Inactivated sentence examples within virion inactivated vero



Symptomatic post-vaccination SARS-CoV-2 infections in healthcare workers– A multicenter cohort study


COVID-19 vaccination and immunomodulatory or immunosuppressive drugs: indications and contraindications

Virion Inactivated sentence examples within virion inactivated vaccine



Developmental biology of Corona vaccine: lipid nanoparticle mRNA-encapsulation, a safe approach


Human Vaccines & Immunotherapeutics: news

Virion Inactivated sentence examples within virion inactivated candidate



Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters


Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters


COVID‐19 vaccine‐induced urticarial vasculitis



Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation



Symptomatic post-vaccination SARS-CoV-2 infections in healthcare workers– A multicenter cohort study



Developmental biology of Corona vaccine: lipid nanoparticle mRNA-encapsulation, a safe approach



COVID-19 vaccination and immunomodulatory or immunosuppressive drugs: indications and contraindications



Human Vaccines & Immunotherapeutics: news



Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial



Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial



Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta in individuals sera vaccinated with BBV152



Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters



Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1 /2 clinical trial



Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses



Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial



Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters



Post-Vaccination Symptomatic SARS-CoV-2 Infections are Minimal and Non-Serious: An Observational Multicenter Indian Cohort Study of 28342 Healthcare Workers



Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152



Passive enhanced safety surveillance of GSK’s quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain, an observational study: protocol for the 2018/2019 influenza season



Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season



Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.



Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India



Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III trial in the Northern and Southern Hemispheres.



Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.


Learn more from Virion Inactivated 病毒粒子灭活

Virion Inactivated 病毒粒子灭活


Virion Inactivated 病毒粒子灭活
Encyclopedia 百科全书